Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2021 Aug 11;105(11):e259–e260. doi: 10.1097/TP.0000000000003923

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

FIGURE 1. — Response to SARS-CoV-2 vaccination in Belatacept Kidney transplant recipients. A, Comparison of anti–severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) mRNA positive immune responses in kidney transplant recipients at month 3 after vaccination who were either on belatacept or on tacrolimus immunosuppressive regimen. B, Anti–SARS-CoV-2 mRNA antibody titers in kidney transplant recipients who received belatacept. The dot-plot shows all anti–SARS-CoV-2 mRNA titers at months 2 and 3 after vaccination. The red point shows the average; the red bar represents the interquartile. C, anti–SARS-CoV-2 mRNA positive immune responses in belatacept-treated kidney transplant recipients after the third vaccination.